Truist Securities Reiterates Marinus Pharmaceuticals (MRNS) at Buy, $35 PT, ZTALMY Approval was Expected but Still a Relief, Sees $200M Peak Sales but a Much Larger Opportunity in Ongoing TSC Trial
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $35.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS), following approval ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
